1. It limits tPA and glutamate
mediated neurotoxicity,
by blocking the binding of
tPA to NMDA receptors,
providing neuroprotection
PamBio’s drug product in development is an inactive recombinant mutant-tPA protein. Its
S481A amino-acid substitution renders the protein catalytically inactive but maintains its
structure and ability to interact with major components of the fibrinolytic pathway.
This therapeutic biomolecule has a dual, antifibrinolytic and neuroprotective effect:
It is the only known
antifibrinolytic drug that
blocks both tPA and uPA
fibrinolysis enzymes’ activity,
enabling treatment in a time-
window beyond 3 hours
Anti-bleeding Neuroprotection
The only known antifibrinolytic
agent that inhibits both, tPA and uPA
enzymes
The only known antifibrinolytic
agent that increases the anti-
bleeding treatment time-window
beyond 3 hours
Minimizing blood toxicity
in the brain
Stabilizing blood clots
(in contrast to creating blood clots)
and preventing bleeding
Preventing NMDA-receptor-
mediated excitotoxic neuronal death
High degree of similarity to the
human tPA protein that minimizes
potential immunogenicity and
organ/tissue toxicity
High target specificity
for reduced side effects
High-affinity binding to targets
to minimize dose
Unique and safe mechanism
of action
Short half-life
Native-tPA as antidote
Mutant-tPA as antidote
Control Treated
Anti-bleeding effect
Mutant-TPA prevents ICH in mice,
post cranial head injury (CHI)
PamBio’s mutant-tPA
drug benefits include
Mutant-tPA prevents neuronal degeneration in
piglets, post fluid percussion injury (FPI)
Mutant-tPA (tPAS481A) attenuates neurologic
deterioration in mice, post CHI
P < 0.0001
Control FPI FPI + tPA-S481A
Higazi et. al., JOURNAL OF NEUROTRAUMA, 2012 Higazi et. al., Blood, 2015Higazi et. al., Blood, 2015
5 3
10 6
15 9
20 12
25 15
30 18
Meannumberofdegeneratingneurons
Neurologicseverityscore
CA1 WT Post CHI+Saline
+ +
*
*
CA3 WT Post CHI+ t PAS481A
Neuroprotection effect
Innovating in therapy
for acute bleeding conditions
Pam-Bio develops
the only known drug treatment
for hemorrhagic stroke

2. PamBio is an innovative biotechnology
company developing the only known drug
therapy for the treatment of hemorrhagic
stroke (intracranial hemorrhage, ICH)
Innovating in therapy for acute bleeding conditions
The financial annual burden of ICH in the US and the
EU is estimated at US$ 43.5 billion
"tPA Mutant in the Treatment
of Acute Brain Injury and
Neurodegenerative Disorders“, 2009
"Plasminogen Activator Mutants
as Anti-Fibrinolytic Agents“, 2014
Inventors: Higazi Abd, Higazi Nuha Inventors: Higazi Abd, Higazi Nuha
(Accepted: EP, US, FR, GR, UK, IN SP; National phase: IL, CA) (National phase: US, CN, EP, IN, IL)
Every year, 15 million
people worldwide suffer
a stroke.
Approximately 6 million
die and another 5 million
are left permanently
disabled
Every 5 seconds a stroke patient
dies worldwide
This equals
deaths/year worldwide
million6.7
Amos Ofer, PhD, MBA – CEO
Has experience in directing and managing
multidisciplinary, scientific and clinical,
research teams. Holds a PhD and a MBA
from the Tel-Aviv University
Prof. Abd Al-Roof Higazi, MD –
Founder & CSO
A leading expert in the field of clinical
biochemistry and the head of the Division
of Laboratories & Department of
Clinical Biochemistry
Nuha Higazi, PhD – Co-founder & CTO
Zohar Gendler, CEO-NGT3 VC – Director
Former CEO and director of Beta-O2
Technologies.
Former CEO of the Technion Entrepreneurial
Incubator (TEIC) for a period of 11 years.
Led the establishment and investment in
more than 40 companies such as Prolor
Biotech, Mazor Robotics and ReWalk
Avri Havron, PhD – Director
The former CEO of PROLOR biotech
inc., which was sold on August 2014 to
OPCO for US$ 480M. A veteran in the
Israeli biotech industry with extensive
experience in drug development
Paul Waymack, MD, DSc – Director
An ex-FDA official, with extensive
experience in FDA regulation and drug
development processes
Noa Shelach, PhD – Director
More than 18 years of experience in leading
pharmaceuticals and medical devices
Contact Us
Amos Ofer, CEO - Amos@pambio.co.il
PamBio was established on August
2014 by NGT3 VC – a Jewish-Arab
incubator located in Nazareth
(www.ngt3vc.com); and Hadasit –
the Technology transfer company
of Hadassah University Hospitals
(www.hadasit.co.il)
IP licensed from Hadassah University Hospitals
Visit our page
www.ngt3vc.com/pambio-innovating
Market and Need
ICH accounts for Many
are left disabled
Death rates
after an ICH
are 31%
at 7 days
and 59%
at one year
of all strokes
ICH
is the most
devastating
form of stroke%
10-15
There is no drug treatment
for hemorrhagic stroke